Frontlight ResearchEarly access
Gastric and oesophageal cancer trials in China
723 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleSKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- Where
- Changchun, Chengdu, Chongqing, Fuzhou, Ha’erbin, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Xi’an, Yichang, Zhengzhou
- Age
- 18 years to 75 years
- People
- 120
- Run by
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
See details and how to joinNCT07700667 - Phase 3Taking peopleQLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ
- Where
- Beijing
- Age
- 18 years and over
- People
- 560
- Run by
- Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT07716449 - Phase 3Taking peopleA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Where
- Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Linfen, Linyi, Nanchang, Nanjing, Shandong, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xi'an, Xining, Yinchuan, Zhengzhou
- Age
- 18 years and over
- People
- 840 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06764875 · EU 2024-512583-57-00 - Phase 3Taking peopleSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Where
- Beijing, Changde, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Lanzhou, Linhai, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shenzhen, Tianjin, Wuhan, Xiamen, Xi'an, Xingtai, Xuzhou, Yinchuan, Zhengzhou
- Age
- 18 years and over
- People
- 2,130 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07431281 · EU 2024-519787-40-00 - Phase 3Taking peopleRadical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Where
- Beijing, Changchun, Changzhi, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shangrao, Tianjin, Ürümqi, Wuhan, Xi'an, Xi’an, Zhangzhou
- Age
- 18 years to 70 years
- People
- 170
- Run by
- Hua Huang, MD, PhD
See details and how to joinNCT07789184 - Phase 2Not yet taking people in ChinaA Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 36
- Run by
- Fudan University
See details and how to joinNCT07878221 - Phase 2Taking peopleConversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
- Where
- Jinan
- Age
- 18 years to 75 years
- People
- 54
- Run by
- Jinbo Yue
See details and how to joinNCT07007182 - Phase 2Taking peopledCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 120
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07162506 - No phaseNot yet taking people in ChinaStomach-Partitioning Versus Conventional Gastrojejunostomy for Malignant Gastric Outlet Obstruction: A Multicenter Randomized Controlled Trial
- Where
- Nanning, Wuzhou
- Age
- 18 years to 75 years
- People
- 80
- Run by
- Guangxi Medical University
See details and how to joinNCT07561073 - Phase 3Taking peopleA Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Where
- Anyang, Beijing, Changzhi, Ganzhou, Hefei, Jinan, Jining, Nanjing, Shenyang, Taiyuan, Tianjin, Wenzhou, Xiamen, Zhengzhou
- Age
- 18 years and over
- People
- 351 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07043400 · EU 2025-522862-58-00 - Phase 2Not yet taking people in ChinaExploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 54
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07872696 - Phase 2/3Taking peopleSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Where
- Chengdu, Guangzhou, Shanghai, Wuhan
- Age
- 18 years and over
- People
- 840 worldwide
- Run by
- Pfizer
See details and how to joinNCT07392892 · EU 2025-524717-86-00 - Phase 1/2Taking peopleA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Where
- Chongqing, Hangzhou, Tianjin, Wuhan
- Age
- 18 years and over
- People
- 1,438 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00 - Phase 1/2Taking peopleA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Where
- Beijing, Hangzhou, Hefei, Huai'an, Shanghai, Xiamen, Xinxiang, Zhengzhou
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05319730 · EU 2023-505189-26-00 - Phase 2Taking peopleEfficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
- Where
- Anyang, Beijing, Feixian, Fujian, Handan, Jining, Taizhou, Tianjin, Xinxiang, Yinchuan
- Age
- 18 years to 80 years
- People
- 57
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06342167 - Phase 2Taking peopleA Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 112
- Run by
- Sun Yat-sen University
See details and how to joinNCT07863141 - No phaseTaking peopleClinical Study on Using Laparoscopic Sentinel Lymph Node Navigation Combined With Dual Endoscopy Surgery for Early Gastric Cancer
- Where
- Qingdao
- Age
- 18 years to 80 years
- People
- 9
- Run by
- wangdongsheng
See details and how to joinNCT07708012 - Phase 2Taking peopleIntestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
- Where
- Shantou
- Age
- 18 years to 75 years
- People
- 39
- Run by
- Chuangzhen Chen
See details and how to joinNCT07339488 - No phaseTaking peopleLECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)
- Where
- Beijing
- Age
- 20 years to 80 years
- People
- 40
- Run by
- Peking University People's Hospital
See details and how to joinNCT07857668 - No phaseTaking peopleRadiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 500
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07858630 - No phaseNot yet taking people in ChinaSintilimab Combined With Chemoradiotherapy as Neoadjuvant Therapy for Locally Advanced Gastroesophageal Junction Cancer
- Where
- Hefei
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Anhui Medical University
See details and how to joinNCT07859410 - Phase 2Taking peopleNeoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 49
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07244978 - Phase 2Taking peopleCamrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 45
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07505186 - No phaseTaking peopleAnti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT07855640 - Early phase 1Taking peopleSafety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
- Where
- Nanjing
- Age
- 18 years and over
- People
- 15
- Run by
- Base Therapeutics (Shanghai) Co., Ltd.
See details and how to joinNCT07166263